Quantcast
Friday, March 29, 2024

FAUCI: Just Take Whatever Vaccine is Available

(Associated Press) Dr. Anthony Fauci says if a coronavirus vaccine is available, regardless of which one, take it.

The top U.S. infectious disease expert told NBC on Thursday a third vaccine becoming available “is nothing but good news” and would help control of the pandemic.

U.S. regulators announced Wednesday that Johnson & Johnson’s single-dose vaccine offers strong protection against severe COVID-19.

It’s expected to be approved soon by the FDA.

Fauci warns people not to hold off on getting the Johnson & Johnson vaccine while waiting for the slightly more effective Pfizer or Moderna shots.

He says it’s a race “between the virus and getting vaccines into people” and “the longer one waits not getting vaccinated, the better chance the virus has to get a variant or a mutation.”

Fauci says public health officials are always concerned about virus variants and stressed following public health measures of wearing masks and social distancing.

The predominant coronavirus variant in the United States is from Britain.

Fauci says the vaccines distributed in the U.S. “clearly can take care of that particular strain.”

Pfizer has announced it has begun studying a third dose of its COVID-19 vaccine, part of a strategy to guard against mutated versions of the coronavirus.

Health authorities say first-generation COVID-19 vaccines still protect against variants that are emerging in different parts of the world.

But manufacturers are starting to prepare now in case a more vaccine-resistant mutation comes along.

Pfizer said it will offer a third dose to 144 volunteers, drawing from people who participated in the vaccine’s early-stage U.S. testing last year.

It wants to determine if an additional booster shot given six to 12 months after the first two doses would rev up the immune system enough to ward off a mutated virus.

Pfizer and its German partner, BioNTech, also are tweaking their vaccine recipe.

The companies are in discussions with U.S. and European regulators about a study to evaluate doses updated to better match variants such as the one first discovered in South Africa.

Copyright 2024. No part of this site may be reproduced in whole or in part in any manner other than RSS without the permission of the copyright owner. Distribution via RSS is subject to our RSS Terms of Service and is strictly enforced. To inquire about licensing our content, use the contact form at https://headlineusa.com/advertising.
- Advertisement -

TRENDING NOW

TRENDING NOW